GLP-1s and mood: what the evidence says about anxiety, depression, and the quiet mind.

The short answer

Is GLP-1 depression a real medication effect? It has not been shown to be one: after evaluating the reports, the FDA found no clear evidence that these medications cause suicidal thoughts, and mood changes in either direction remain reports under study rather than settled effects. That cuts both ways, and this article holds the line in both directions. Some people on a GLP-1 describe a lower, flatter mood in the first months. Others describe the opposite, a mind gone unexpectedly quiet and calm. Neither experience is proof of what the molecule does, both deserve to be taken seriously, and the useful skill is knowing how to watch your own mood honestly and when to say something. That is what follows.

The two stories people tell

Sit with enough people starting these medications and two mood stories repeat, told with equal conviction, often in the same week of treatment, sometimes by the same person a month apart. Both stories deserve to be written down before the evidence gets discussed, because the evidence exists precisely because people kept telling them.

The first is relief. The constant background negotiation with food, what to eat, when, whether you have been good, goes quiet, and people describe having attention and patience back that they did not know food was consuming. Some describe it as the first calm in years. We wrote about that experience, and the biology under it, in food noise, explained.

The second story is dimmer. Some people report low mood, flatness, or anxiety in the early months: food no longer brings the comfort it used to, eating out loses its pleasure, a lifelong coping tool goes missing, energy dips while the body adapts. A smaller number report feeling simply not themselves in ways they cannot pin to any of that.

Here is the honest frame for both: these are reports, not verdicts. People start GLP-1 treatment in the middle of real lives, often at moments of high hope and high stress, while eating much less than before and sleeping differently. Untangling what the molecule did from what the months did is genuinely hard, which is exactly why regulators studied the question at scale rather than settling it by anecdote, and why we describe both stories as under study rather than declaring either one a drug effect. Our guide to GLP-1 side effects applies the same discipline to the physical list.

What the FDA review concluded

When enough people reported low mood and suicidal thoughts on these medications, the FDA did what it does with post-market signals: it opened a formal evaluation of the reports. The FDA's preliminary review, published in January 2024, said its preliminary evaluation did not suggest a causal link between GLP-1 medications and suicidal thoughts or actions, while noting it could not definitively rule one out and that the review was continuing.

That review has since concluded. In a communication published in January 2026, the FDA reported that its comprehensive evaluation found no increased risk of suicidal ideation or behavior associated with GLP-1 medications, and it asked the manufacturers of the branded products whose labels carried that warning language, including branded semaglutide 2.4 mg and branded tirzepatide, to remove it. In plain terms: the agency looked hard, at trials and at post-market data, and did not find the causal link the reports had raised.

Two caveats keep this honest. First, those findings come from studies and surveillance of branded, FDA-approved products, not compounded preparations; the molecules are the same, but the data belongs to the branded programs. Second, a population-level finding of no increased risk is not a promise about any single person. It means the medication is not established to cause suicidal thoughts; it does not mean your mood is off the table. Mood still gets watched, person by person, and that is the second half of this article.

Compounded medications are prepared by state-licensed US compounding pharmacies and are not FDA-approved or evaluated for safety, effectiveness, or quality.

It is also worth knowing what the original trials could and could not see. The phase 3 obesity trials of the branded products screened out people with recent severe depression or a history of suicide attempts, and tracked mood with standardized questionnaires along the way. That design protects trial participants and it means the trials speak most directly about people who started in reasonable mental health, which is one more reason post-market surveillance mattered and one more reason individual monitoring still does.

Food noise, reward, and why some feel calmer

The calmer-mind story has a plausible mechanism, and it is worth stating carefully, because a mechanism is not a medical claim.

GLP-1 receptors are not confined to the gut. They sit in brain regions involved in appetite and in reward, the circuitry that assigns wanting to things. The medications quiet the constant appetite broadcast, and many members describe a parallel quieting of the compulsive pull toward food, the loops of craving and negotiation that ran in the background of every day. When a loop that loud goes quiet, people notice the silence, and some of them call it calm.

There is a second, humbler mechanism worth naming: attention is finite. A mind that spent hours a day negotiating with the pantry gets those hours back, and reclaimed attention can feel like lifted mood without any direct effect on mood chemistry at all. Researchers are actively studying how these medications act on reward signaling, including whether the quieting extends beyond food to other compulsive pulls; that work is young, unsettled, and easy to overstate, which is why we are not going to.

So here is the line we will not cross: a GLP-1 is not a treatment for anxiety or depression, we do not prescribe it for mood, and no one should start one expecting a mental health benefit. The quiet is a commonly reported experience with a plausible mechanism under active study, nothing more, nothing less. If the chatter of food noise has run your days, that reported quiet is worth understanding for what it is. If you live with an anxiety disorder or depression, this medication is not a substitute for treating them, and your existing mental health care should stay exactly where it is.

Mood, sleep, and under-eating

Before any mood change on treatment gets attributed to the molecule, three ordinary suspects deserve the first look, because they are common, fixable, and mood-shaped.

Under-eating is the big one. Appetite suppression works, sometimes too well, and a person eating far below their needs will eventually feel it as flatness, irritability, and fatigue that reads as low mood. Protein carries the load here; under-fueling protein specifically is the quiet cause behind a lot of week-six gloom. If your mood dimmed around the time your plates got very small, that is a dose-and-nutrition conversation, not a psychiatric mystery.

Sleep changes on these medications too, usually for the better as weight comes down, but the adjustment months can be uneven, and broken sleep is the fastest route to a darker outlook that exists. We wrote about the sleep and cortisol connection separately, and it is required reading if your mood and your sleep dipped together.

And then there is the role food itself was playing. For many people, eating was a daily comfort, a social anchor, and a reliable coping tool. When treatment turns that volume down, the loss is real even when the trade is wanted. Grieving a coping mechanism can look like sadness, because partly it is. Naming that honestly, to yourself and to your clinician, beats pretending the only possible explanations are chemistry or weakness.

A related shift hides in the social calendar. Dinners out, drinks, the standing food rituals with the people you love: many members find these change shape on treatment, sometimes shrinking before new rituals grow in. Less alcohol is common on these medications, and for most people that is a gain, but a quieter calendar can read as loneliness if nothing replaces what the table used to do. None of this is a drug effect on mood. All of it can move a mood, which is exactly why it belongs on the checklist before the molecule does.

How to track your own mood honestly

Self-observation is unreliable precisely when it matters most, so give it structure before you need it. The goal is not clinical self-diagnosis; it is producing a record honest enough that you and your clinician can tell a rough week from a real trend.

Take a baseline before your first dose. Write three sentences about your mood in an ordinary week: energy, interest in things, irritability, sleep. Date nothing for the Journal's sake; date everything in your own notes.

Then check in on a schedule, weekly, not when you happen to feel bad. Two questions do most of the work: has my interest in things I usually enjoy changed, and would the person who knows me best say I seem different? The second question matters because flatness hides from the person inside it. Ask that person directly; tell them you are starting a new treatment and you want them to say something if you seem off.

Watch for the difference between tired and dim. Tired lifts with rest, food, and a good week. Dim persists through them: things you love stop pulling at you, and the flatness has no schedule. Tired is usually the body adapting. Dim, for more than two weeks, is information your clinician needs.

“Mood belongs in your chart the same way weight does. Tell us what lifted and what dimmed, and we will treat both as information.”

Dr. Marcus Okafor, MD

One more habit: track it even if you feel great. The calmer-mind report is worth documenting with the same skepticism as the low-mood report. If the quiet is real for you, your notes will show it; if it fades, that is information too.

When to message your clinician

The threshold for mentioning mood is low, and it should be. Parke intake asks about mental health history directly, a licensed clinician reviews every answer, and the same clinician wants mood updates on treatment; the eligibility screen exists so this conversation starts before the first dose, whether your protocol is tirzepatide or semaglutide.

Message your clinician, without waiting for a scheduled check-in, when: low mood or flatness persists past two weeks; you have lost interest in things you reliably enjoy; anxiety is interfering with sleep, work, or relationships; eating has fallen so far that you suspect under-fueling; or someone who knows you well says you seem different. None of those are emergencies. All of them are exactly what the portal is for, and every one of them is easier to address early. The answer may be a dose change, a slower schedule, a nutrition fix, a referral to mental health care, or reassurance; what it will never be is a suggestion that you tough it out. And if you already work with a therapist or a mental health prescriber, keep them in the loop too; they are watching a channel your treatment clinician cannot see, and the two conversations are stronger together.

One situation sits above the portal entirely. If you are having thoughts of harming yourself, that is not a message to send and wait on. Call or text 988, the Suicide and Crisis Lifeline, available 24 hours a day, and seek care now; tell your clinician afterward, and we will work the treatment question from there.

The bottom line

The evidence, stated plainly: the FDA evaluated the reports and found no increased risk of suicidal thoughts or actions with GLP-1 medications, and no mood effect in either direction, darker or calmer, is established as a drug effect. The reports are real, the mechanisms are plausible, and the studies continue. Meanwhile your own mood is a single unstudied sample, and it deserves the same attention as your weight: a baseline, a weekly look, an honest witness, and a low threshold for saying something. Most mood dips on treatment trace to under-eating, poor sleep, or the strangeness of losing food as a coping tool, and all three have answers. The rare exception is exactly why your clinician wants to hear from you early.

GLP-1 depression and anxiety: common questions

Can semaglutide cause depression?

A causal link has not been established. The FDA's comprehensive review of branded GLP-1 products found no increased risk of suicidal ideation or behavior, and depressed mood on treatment is a report under study, not a known effect. Low mood in the early months more often traces to under-eating, disrupted sleep, or losing food as a coping tool. Persistent flatness belongs in a message to your clinician either way.

Do GLP-1s help with anxiety?

No. These medications are not a treatment for anxiety, and no mental health benefit has been established. Some members report feeling calmer as food noise quiets, and researchers are studying how the medications act on reward circuits, but a reported experience with a plausible mechanism is not a claim. If you live with anxiety, keep your mental health care in place and tell your clinician about it at intake.

Can I take a GLP-1 with an antidepressant?

Many members take both. The answer for you belongs to your clinician, and it starts with a complete list: tell your clinician everything you take, including every mental health medication, at intake and whenever anything changes. Specific combinations, timing, and monitoring are clinical decisions made with your full history in view, not something to settle from an article.

If you are having thoughts of harming yourself, call or text 988, the Suicide and Crisis Lifeline, available 24 hours a day.

This article is general education, not medical advice, and it is not a complete list of risks or side effects. Trial figures cited here come from studies of branded, FDA-approved products; compounded medications are prepared by state-licensed US compounding pharmacies and are not FDA-approved or evaluated for safety, effectiveness, or quality. Whether any treatment is appropriate for you is a decision made with a licensed clinician who knows your history. If you are experiencing a medical emergency, call 911. Review the important safety information on each treatment page.